[Immunotherapy for HNSCC : Quo vadis?]. / Immuntherapie des HNSCC : Quo vadis?
HNO
; 64(10): 700-7, 2016 Oct.
Article
en De
| MEDLINE
| ID: mdl-27624904
ABSTRACT
BACKGROUND:
Immunotherapy remains a hot topic with an endless stream of new upcoming clinical trials. The results of studies to date are promising for second-line palliative treatment of head and neck squamous cell carcinoma (HNSCC). The next step is testing these strategies in randomized trials for first-line and curative treatment in an adjuvant, neoadjuvant, and primarily nonsurgical setting. So far, established biomarkers have not proven reliable enough to predict response rates precisely.OBJECTIVES:
On occasion of the annual meeting of the American Society of Clinical Oncology (ASCO), we aimed to invesitage the future of immunotherapies.METHODS:
We collected the most promising upcoming studies alongside current research in the field of biomarkers with a view to interesting new immunotherapeutic strategies.RESULTS:
The search for appropriate biomarkers in particular seems to be a central research objective in the short term. There is a broad range of new agents that will be tested in clinical trials as well as the combination of immunotherapy with chemo- and chemoradiotherapy or other immune-modulating drugs.CONCLUSION:
The real challenge will be to find the most fitting therapy for each patient out of a large panel of available regimens. Therefore, it is most important to find a set of reliable biomarkers that together could predict treatment response.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Carcinoma de Células Escamosas
/
Biomarcadores de Tumor
/
Vacunas contra el Cáncer
/
Terapia Molecular Dirigida
/
Neoplasias de Cabeza y Cuello
/
Anticuerpos Monoclonales
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
/
Prognostic_studies
Límite:
Humans
Idioma:
De
Año:
2016
Tipo del documento:
Article